FDA, DEA Drafting Agreement To Share Information On Controlled Substances
This article was originally published in The Pink Sheet Daily
Executive Summary
Congressional hearing promotes bill that would mandate swift scheduling of FDA-approved products; one infamous controlled substance, Zohydro ER, heads to court as Zogenix files suit to halt Massachusetts’ ban.